CINC News and Press, CinCor Pharma Inc. From 07/02/22

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...

figHTN-CKD is CinCor’s fourth ongoing Phase 2 clinical trial evaluating baxdrostat (CIN-107) Initial topline data for figHTN-CKD expected in 2H 2023 WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) announced today that t...

WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York, New York. The CinCor management team will give a corporate presentation on June 9, 2022, at 9 A...

The following slide deck was published by CinCor Pharma, Inc. in conjunction with this event. For further details see: CinCor Pharma (CINC) Investor Presentation - Slideshow

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that management will present at the H.C. Wainwright 2022 Global Investment Conference taking place on May 23-26 virtually and in Miami, Florida, and at the UBS 2022 Global Healthcare Conferen...

CinCor Pharma press release (NASDAQ:CINC): Q1 GAAP EPS of -$0.50. Cash, cash equivalents and marketable securities were $314.2 million as of March 31, 2022, as compared to $136.6 million as of December 31, 2021. For further details see: CinCor Pharma GAAP EPS of -$0.50

Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data for baxdrostat (CIN-107) in HALO Phase 2 trial for uncontrolled hypertension (uHTN) expected in 2H 2022 Phase 2 figHTN-CKD trial ev...

CinCor (CINC) stock rallied 15% on Monday, with the stock having risen 29% over the last five sessions.  Shares of CINC opened at $21.99 and climbed steadily during morning trading. The stock recently changed hands at $24.99, up 15%, at approximately 1:40 p.m. CINC held its initial publi...

WALTHAM, Mass., April 19, 2022 (GLOBE NEWSWIRE) --  CinCor Pharma, Inc. (“CinCor”) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in Miami, Florida. The CinCor management team will participate in one-on-one...